CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 30 enrolled
Drug / intervention
rituximab +1 morebiological
Likely dose
rituximab 375 mg/m2from record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00720876
NCT00720876Phase 2Completed
CompareCT.gov

A Phase II Study of Vorinostat (Suberoylanilide Hydroxamic Acid) Plus Rituximab in Indolent Non-Hodgkin's Lymphoma

City of Hope Medical Center·interventional·Posted Jul 23, 2008·Updated Aug 7, 2018

In Brief

A Phase 2 clinical trial evaluating rituximab and vorinostat for Lymphoma. Completed, enrolled 30 participants across 3 sites.

Detailed Summary

RATIONALE: Vorinostat may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them. Giving vorinostat together with rituximab may kill more cancer cells. PURPOSE: This phase II trial is studying the side effects of giving vorinostat together with rituximab and to see how well it works in treating patients with indolent non-Hodgkin lymphoma.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLymphoma
CountriesUnited States
CollaboratorsNational Cancer Institute (NCI), Merck Sharp & Dohme LLC

Timeline

Phase 2CompletedFinished
2009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJul 23, 2008
Enrollment StartJul 23, 2008
Primary CompletionJun 8, 2017
TodayJul 2, 2026
Enrollment to primary: 8.9 yearsPosted 17.9 years ago

Interventions

rituximabbiological

Rituximab will be administered at a dose of 375 mg/m2 on day 1 of every cycle, every 3 weeks.

vorinostatdrug

200 mg twice daily, orally for 14 days followed by a seven day break on a 21 day cycle.